EILF HCC PRECEPTORSHIP

June 18, 2018 10:40 am Published by Leave your thoughts1 Comment% Comments

Tags:

Categorised in:

This post was written by SOTO Admin

KIDNEY MEETS LIVER

June 18, 2018 10:20 am Published by Leave your thoughts1 Comment% Comments

Tags:

Categorised in:

This post was written by SOTO Admin

Tackling the NASH epidemic, introducing the NAFLD POLICY REVIEW study

July 18, 2017 6:11 pm Published by Leave your thoughts1 Comment% Comments

The global prevalence of non-alcoholic fatty liver disease (NAFLD) is 25%. It is considered to be endemic in Europe and a major potential threat to public health. Yet it appears to receive very limited attention. EASL International Liver Foundation aims to place the spotlight on NALFD and take the first important step needed to generate a call to action by developing an understanding of what government and key stakeholders such as medical associations and patient groups are currently doing.

The NAFLD POLICY REVIEW study, led by Professor Jeffrey Lazarus, will systematically review the relevant policies European countries have in place to address NAFLD and non-alcoholic steatohepatitis (NASH), the most serious form of NAFLD.
The results of the reivew will be presented in conjunction with the First EASL NAFLD summit, which is being held in Rome, 9-11 November, 2017.

To learn more, contact us.

Tags:

Categorised in:

This post was written by SOTO Admin

Supporting Viral Hepatitis elimination in Mongolia

July 18, 2017 11:17 am Published by Leave your thoughts1 Comment% Comments

Mongolia has the world’s highest rate of liver cancer mortality; nearly eight times the global average. The prevalence of chronic viral hepatitis B, C, and D is at endemic level, and constitutes the main reason cause of Mongolia’s world-leading liver cancer mortality rate. To tackle this deadly crisis, the Onom Foundation, Patient and Civil Society Council, Mongolian Gastroenterology Association, and Mongolian Society of Hepatology launched the Hepatitis Prevention, Control, and Elimination (HPCE).

The foundation is collaborating with the Mongolian society of Hepatology, Mongolian Gastroenterology Association, the Onom Foundation and EASL to hold first European Union – Mongolia Hepatology Conference, which will take place on August 17 – 19, 2017 in Ulaanbaatar, Mongolia. The conference will bring together clinicians, scientists, and specialists to advance the HPCE Program in Mongolia, and lay the ground work for other countries to follow.

Dr Naranbaatar Dashdorj, Co-Founder and Chair of the Board of the Onom Foundation states: “Mongolia, a champion country in hepatitis elimination, is honored to cooperate with the European Association for the Study of the Liver and EASL International Liver Foundation in achieving the MISSION 2020 of the HPCE Program. Our cooperation not only helps Mongolia to reach its hepatitis elimination goals but also demonstrates to the world that together we can eliminate viral hepatitis as a public health threat by 2030, a goal that was unanimously approved by all 190 member states of the World Health Organization in May of 2016.”

Tags:

Categorised in:

This post was written by SOTO Admin

Elimination of Viral Hepatitis in Chronic Kidney Disease patients: a call to action

July 17, 2017 10:11 pm Published by Leave your thoughts1 Comment% Comments

We are honoured to announce that we have joined forces with the European Renal Association- European Dialysis and Transplant Association (ERA-EDTA) to bring together expert Hepatologists and Nephrologists to eliminate viral hepatitis among patients with chronic kidney disease (CKD).

Professor Michel Jadoul, who is jointly leading this initiative with Professor Stanislas Pol, said “The burden associated with HCV (mortality, morbidity and quality of life) remains substantial in CKD, dialysis and kidney transplant patients . Fortunately, very recent studies extend the dramatic improvement of the treatment of hepatitis C to CKD populations . Thus, there should be no reason for complacency anymore. Success is now at hand, under the partnership of key actors in the field of liver and kidney diseases.”

The initiative will kick-off on November 1st in conjunction with the Kidney Week Meeting in New Orleans. Together, we aim to not only kick-start the call to action but provide the information, training, tools, and strategic guidance to radically alter the prevention and treatment of viral hepatitis in this vulnerable population.

Tags:

Categorised in:

This post was written by SOTO Admin